NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/18/2026 10:49
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization12,374 mln
Float90.66 mln
Earnings Date11/04/2026
EPS
0.45
Overpriced
P / E
262
Bubble territory
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-3.3
Reliable
Relative Strength
85
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
Business Description
Corcept Therapeutics is a US-based pharmaceutical company focused on developing drugs that target the effects of cortisol, a hormone that can cause serious harm when the body produces too much of it. Its main product, Korlym, is an approved oral treatment for adults with Cushing's syndrome whose excess cortisol has led to blood sugar problems and who cannot or did not benefit from surgery. The company also has several additional compounds in various stages of clinical testing, targeting conditions such as liver disease and ALS. Founded in 1998 and based in Redwood City, California, Corcept has built its entire business around understanding and controlling cortisol's role in disease.